↓ Skip to main content

First-in-human study to assess the safety, tolerability, pharmacokinetics and immunogenicity of DS002, an anti-nerve growth factor monoclonal antibody

Overview of attention for article published in Frontiers in Pharmacology, December 2022
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
3 Dimensions

Readers on

mendeley
8 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
First-in-human study to assess the safety, tolerability, pharmacokinetics and immunogenicity of DS002, an anti-nerve growth factor monoclonal antibody
Published in
Frontiers in Pharmacology, December 2022
DOI 10.3389/fphar.2022.1075309
Pubmed ID
Authors

Tingting Ma, Bei Cao, Lei Huang, Yuanxun Yang, Yan Geng, Pinhao Xie, Yu Zhao, Hui Lin, Kun Wang, Chunhe Wang, Runbin Sun, Juan Li

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 8 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 8 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 2 25%
Professor 1 13%
Professor > Associate Professor 1 13%
Researcher 1 13%
Unknown 3 38%
Readers by discipline Count As %
Agricultural and Biological Sciences 2 25%
Sports and Recreations 1 13%
Neuroscience 1 13%
Design 1 13%
Unknown 3 38%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 December 2022.
All research outputs
#20,723,550
of 23,323,574 outputs
Outputs from Frontiers in Pharmacology
#10,568
of 16,763 outputs
Outputs of similar age
#344,514
of 436,554 outputs
Outputs of similar age from Frontiers in Pharmacology
#558
of 1,060 outputs
Altmetric has tracked 23,323,574 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 16,763 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.1. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 436,554 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1,060 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.